Smart nanocarrier-based drug delivery systems for cancer therapy and toxicity studies: A review

Siegel, 2015, Cancer statistics, 2015, CA Cancer J Clin, 65, 5, 10.3322/caac.21254

American Cancer Society, 2017, Cancer facts and figures 2017, Genes Dev, 21, 2525

Chabner, 2005, Timeline: chemotherapy and the war on cancer, Nat Rev Cancer, 5, 65, 10.1038/nrc1529

DeVita, 2008, A history of cancer chemotherapy, Cancer Res, 68, 8643, 10.1158/0008-5472.CAN-07-6611

Zhang, 2011, The application of carbon nanotubes in target drug delivery systems for cancer therapies, Nanoscale Res Lett, 6, 555, 10.1186/1556-276X-6-555

Ahmad, 2016, Anticancer chemotherapy in teenagers and young adults: managing long term side effects, BMJ, 354, i4567, 10.1136/bmj.i4567

Gillet, 2010

Alfarouk, 2015, Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp, Cancer Cell Int, 15, 71, 10.1186/s12935-015-0221-1

Nooter, 1996, Molecular mechanisms of multidrug resistance in cancer chemotherapy, Pathol Res Pract, 192, 768, 10.1016/S0344-0338(96)80099-9

Gupta, 1990, Drug targeting in cancer chemotherapy: a clinical perspective, J Pharm Sci, 79, 949, 10.1002/jps.2600791102

Kreuter, 2007, Nanoparticles-a historical perspective, Int J Pharm, 331, 1, 10.1016/j.ijpharm.2006.10.021

Khanna, 1970, Bead polymerization technique for sustained-release dosage form, J Pharm Sci, 59, 614, 10.1002/jps.2600590508

Matsumura, 1986, A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs, Cancer Res, 46, 6387

Bae, 2011, Targeted drug delivery to tumors: myths, reality and possibility, J Control Release, 153, 198, 10.1016/j.jconrel.2011.06.001

Ding, 2016, Recent advances in stimuli-responsive release function drug delivery systems for tumor treatment, Molecules, 21, 1715, 10.3390/molecules21121715

Kreyling, 2010, A complementary definition of nanomaterial, Nano Today, 5, 165, 10.1016/j.nantod.2010.03.004

Peer, 2007, Nanocarriers as an emerging platform for cancer therapy, Nat Nanotechnol, 2, 751, 10.1038/nnano.2007.387

Lee, 2015, Smart nanoparticles for drug delivery: boundaries and opportunities, Chem Eng Sci, 125, 158, 10.1016/j.ces.2014.06.042

Liu, 2016, The smart drug delivery system and its clinical potential, Theranostics, 6, 1306, 10.7150/thno.14858

Abuchowski, 1977, Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase, J Biol Chem, 252, 3582, 10.1016/S0021-9258(17)40292-4

Moghimi, 2003, Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties, Prog Lipid Res, 42, 463, 10.1016/S0163-7827(03)00033-X

Moghimi, 2001, Long-circulating and target-specific nanoparticles: theory to practice, Pharmacol Rev, 53, 283

Knop, 2010, Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives, Angew Chemie Int Ed, 49, 6288, 10.1002/anie.200902672

Verhoef, 2013, Questioning the use of PEGylation for drug delivery, Drug Deliv Transl Res, 3, 499, 10.1007/s13346-013-0176-5

Xu, 2014, Nanocarriers in gene therapy: a review, J Biomed Nanotechnol, 10, 3483, 10.1166/jbn.2014.2044

Qi, 2017, Co-delivery nanoparticles of anti-cancer drugs for improving chemotherapy efficacy, Drug Deliv, 24, 1909, 10.1080/10717544.2017.1410256

Kang, 2015, Nanocarrier-mediated co-delivery of chemotherapeutic drugs and gene agents for cancer treatment, Acta Pharm Sin B, 5, 169, 10.1016/j.apsb.2015.03.001

Janib, 2010, Imaging and drug delivery using theranostic nanoparticles, Adv Drug Deliv Rev, 62, 1052, 10.1016/j.addr.2010.08.004

Srinivasan, 2015, Multifunctional nanomaterials and their applications in drug delivery and cancer therapy, Nanomaterials, 5, 1690, 10.3390/nano5041690

Parvanian, 2017, Multifunctional nanoparticle developments in cancer diagnosis and treatment, Sens Bio-Sensing Res, 13, 81, 10.1016/j.sbsr.2016.08.002

Bangham, 1965, The action of steroids and streptolysin S on the permeability of phospholipid structures to cations, J Mol Biol, 13, 253, 10.1016/S0022-2836(65)80094-8

Gregoriadis, 1973, Drug entrapment in liposomes, FEBS Lett, 36, 292, 10.1016/0014-5793(73)80394-1

Akbarzadeh, 2013, Liposome: classification, preparation, and applications, Nanoscale Res Lett, 8, 102, 10.1186/1556-276X-8-102

Sharma, 1997, Liposomes in drug delivery: progress and limitations, Int J Pharm, 154, 123, 10.1016/S0378-5173(97)00135-X

Huang, 2014, Progress involving new techniques for liposome preparation, Asian J Pharm Sci, 9, 176, 10.1016/j.ajps.2014.06.001

Carugo, 2016, Liposome production by microfluidics: potential and limiting factors, Sci Rep, 6, 25876, 10.1038/srep25876

Bangham, 1978, Properties and uses of lipid vesicles: an overview, Ann N Y Acad Sci, 308, 2, 10.1111/j.1749-6632.1978.tb22010.x

Szoka, 1978, Procedure for preparation of liposomes with large internal aqueous space and high capture by reverse-phase evaporation, Proc Natl Acad Sci U S A, 75, 4194, 10.1073/pnas.75.9.4194

Deamer, 1978, Preparation and properties of ether-injection liposomes, Ann N Y Acad Sci, 308, 250, 10.1111/j.1749-6632.1978.tb22027.x

Zumbuehl, 1981, Liposomes of controllable size in the range of 40 to 180 nm by defined dialysis of lipid/detergent mixed micelles, BBA, 640, 252, 10.1016/0005-2736(81)90550-2

Lesoin, 2011, Preparation of liposomes using the supercritical anti-solvent (SAS) process and comparison with a conventional method, J Supercrit Fluids, 57, 162, 10.1016/j.supflu.2011.01.006

Otake, 2006, Preparation of liposomes using an improved supercritical reverse phase evaporation method, Langmuir, 22, 2543, 10.1021/la051654u

Sercombe, 2015, Advances and challenges of liposome assisted drug delivery, Front Pharmacol, 6, 286, 10.3389/fphar.2015.00286

Bozzuto, 2015, Liposomes as nanomedical devices, Int J Nanomed, 10, 975, 10.2147/IJN.S68861

Allen, 2013, Liposomal drug delivery systems: from concept to clinical applications, Adv Drug Deliv Rev, 65, 36, 10.1016/j.addr.2012.09.037

Noble, 2014, Ligand-targeted liposome design: challenges and fundamental considerations, Trends Biotechnol, 32, 32, 10.1016/j.tibtech.2013.09.007

Sapra, 2003, Ligand-targeted liposomal anticancer drugs, Prog Lipid Res, 42, 439, 10.1016/S0163-7827(03)00032-8

Sawant, 2012, Challenges in development of targeted liposomal therapeutics, AAPS J, 14, 303, 10.1208/s12248-012-9330-0

Ruoslahti, 2012, Peptides as targeting elements and tissue penetration devices for nanoparticles, Adv Mater, 24, 3747, 10.1002/adma.201200454

Lee, 2017, Stimuli-responsive liposomes for drug delivery, Wiley Interdiscip Rev Nanomed Nanobiotechnol, 9, e1450, 10.1002/wnan.1450

Huang, 2004, Acoustically active liposomes for drug encapsulation and ultrasound-triggered release, Biochim Biophys Acta – Biomembr, 1665, 134, 10.1016/j.bbamem.2004.07.003

Jin, 2016, Microwave-triggered smart drug release from liposomes co-encapsulating doxorubicin and salt for local combined hyperthermia and chemotherapy of cancer, Bioconjug Chem, 27, 2931, 10.1021/acs.bioconjchem.6b00603

Ogihara-Umeda, 1996, Optimal radiolabeled liposomes for tumor imaging, J Nucl Med, 37, 326

Petersen, 2012, Liposome imaging agents in personalized medicine, Adv Drug Deliv Rev, 64, 1417, 10.1016/j.addr.2012.09.003

Li, 2012, Novel multifunctional theranostic liposome drug delivery system: construction, characterization, and multimodality MR, near-infrared fluorescent, and nuclear imaging, Bioconjug Chem, 23, 1322, 10.1021/bc300175d

Muthu, 2013, Theranostic liposomes for cancer diagnosis and treatment: current development and pre-clinical success, Expert Opin Drug Deliv, 10, 151, 10.1517/17425247.2013.729576

Samson, 2018, Liposomal co-delivery-based quantitative evaluation of chemosensitivity enhancement in breast cancer stem cells by knockdown of GRP78/CLU, J Liposome Res, 1, 10.1080/08982104.2017.1420081

Zununi Vahed, 2017, Liposome-based drug co-delivery systems in cancer cells, Mater Sci Eng C, 71, 1327, 10.1016/j.msec.2016.11.073

Shin, 2016, Polymeric micelle nanocarriers in cancer research, Front Chem Sci Eng, 10, 348, 10.1007/s11705-016-1582-2

Cagel, 2017, Polymeric mixed micelles as nanomedicines: achievements and perspectives, Eur J Pharm Biopharm, 113, 211, 10.1016/j.ejpb.2016.12.019

Trivedi, 2010, Nanomicellar formulations for sustained drug delivery: strategies and underlying principles, Nanomedicine, 5, 485, 10.2217/nnm.10.10

Kataoka, 2001, Block copolymer micelles for drug delivery: design, characterization and biological significance, Adv Drug Deliv Rev, 47, 113, 10.1016/S0169-409X(00)00124-1

Chen, 2017, Reverse micelle-based water-soluble nanoparticles for simultaneous bioimaging and drug delivery, Org Biomol Chem, 15, 3232, 10.1039/C7OB00169J

Tang, 2009, Shell-detachable micelles based on disulfide-linked block copolymer as potential carrier for intracellular drug delivery, Bioconjug Chem, 20, 1095, 10.1021/bc900144m

Deng, 2014, PEG-b-PCL copolymer micelles with the ability of pH-controlled negative-to-positive charge reversal for intracellular delivery of doxorubicin, Biomacromolecules, 15, 4281, 10.1021/bm501290t

Sutton, 2007, Functionalized micellar systems for cancer targeted drug delivery, Pharm Res, 24, 1029, 10.1007/s11095-006-9223-y

Letchford, 2007, A review of the formation and classification of amphiphilic block copolymer nanoparticulate structures: micelles, nanospheres, nanocapsules and polymersomes, Eur J Pharm Biopharm, 65, 259, 10.1016/j.ejpb.2006.11.009

Liu, 2004, Polymer–drug compatibility: a guide to the development of delivery systems for the anticancer agent, ellipticine, J Pharm Sci, 93, 132, 10.1002/jps.10533

Kohori, 2002, Process design for efficient and controlled drug incorporation into polymeric micelle carrier systems, J Control Release, 78, 155, 10.1016/S0168-3659(01)00492-8

Cajot, 2013, In vitro investigations of smart drug delivery systems based on redox-sensitive cross-linked micelles, Macromol Biosci, 13, 1661, 10.1002/mabi.201300250

Husseini, 2002, Investigating the mechanism of acoustically activated uptake of drugs from Pluronic micelles, BMC Cancer, 2, 20, 10.1186/1471-2407-2-20

Seo, 2015, Tumor-targeting co-delivery of drug and gene from temperature-triggered micelles, Macromol Biosci, 15, 1198, 10.1002/mabi.201500137

Blanco, 2009, Multifunctional micellar nanomedicine for cancer therapy, Exp Biol Med, 234, 123, 10.3181/0808-MR-250

Rapoport, 2007, Multifunctional nanoparticles for combining ultrasonic tumor imaging and targeted chemotherapy, JNCI J Natl Cancer Inst, 99, 1095, 10.1093/jnci/djm043

Palmerston Mendes, 2017, Dendrimers as nanocarriers for nucleic acid and drug delivery in cancer therapy, Molecules, 22, 1401, 10.3390/molecules22091401

Jackson, 1998, Visualization of dendrimer molecules by transmission electron microscopy (TEM): staining methods and cryo-TEM of vitrified solutions, Macromolecules, 31, 6259, 10.1021/ma9806155

Nanjwade, 2009, Dendrimers: emerging polymers for drug-delivery systems, Eur J Pharm Sci, 10.1016/j.ejps.2009.07.008

Majoros, 2008, New dendrimers: synthesis and characterization of POPAM-PAMAM hybrid dendrimers, Macromolecules, 41, 8372, 10.1021/ma801843a

Caminade, 2017, Phosphorus dendrimers for nanomedicine, Chem Commun, 53, 9830, 10.1039/C7CC04949H

Richardt, 2009, 81

Tomalia, 1985, A new class of polymers: starburst-dendritic macromolecules, Polym J, 17, 117, 10.1295/polymj.17.117

Hawker, 1990, Preparation of polymers with controlled molecular architecture. A new convergent approach to dendritic macromolecules, J Am Chem Soc, 112, 7638, 10.1021/ja00177a027

Buhleier, 1978, “Cascade”- and “nonskid-chain-like” syntheses of molecular cavity topologies, Synthesis (Stuttg), 1978, 155, 10.1055/s-1978-24702

Bosman, 1999, About dendrimers: structure, physical properties, and applications, Chem Rev, 99, 1665, 10.1021/cr970069y

Esfand, 2001, Poly(amidoamine) (PAMAM) dendrimers: from biomimicry to drug delivery and biomedical applications, Drug Discov Today, 6, 427, 10.1016/S1359-6446(01)01757-3

Newkome, 1985, Micelles. Part 1. Cascade molecules: a new approach to micelles. A [27]-arborol, J Org Chem, 50, 2003, 10.1021/jo00211a052

Abbasi, 2014, Dendrimers: synthesis, applications, and properties, Nanoscale Res Lett, 9, 247, 10.1186/1556-276X-9-247

Jain, 2010, Dendrimer toxicity: let’s meet the challenge, Int J Pharm, 394, 122, 10.1016/j.ijpharm.2010.04.027

Bugno, 2015, Tweaking dendrimers and dendritic nanoparticles for controlled nano-bio interactions: potential nanocarriers for improved cancer targeting, J Drug Target, 23, 642, 10.3109/1061186X.2015.1052077

Wang, 2016, Stimuli-responsive dendrimers in drug delivery, Biomater Sci, 4, 375, 10.1039/C5BM00532A

Ramireddy, 2012, Stimuli sensitive amphiphilic dendrimers, New J Chem, 36, 340, 10.1039/c2nj20879b

Pandita, 2014, Dendrimers in drug delivery and targeting: drug-dendrimer interactions and toxicity issues, J Pharm Bioallied Sci, 6, 139, 10.4103/0975-7406.130965

Ye, 2013, Targeted biodegradable dendritic MRI contrast agent for enhanced tumor imaging, J Control Release, 169, 239, 10.1016/j.jconrel.2013.01.034

Brühwiler, 2010, Postsynthetic functionalization of mesoporous silica, Nanoscale, 2, 887, 10.1039/c0nr00039f

Watermann, 2017, Mesoporous silica nanoparticles as drug delivery vehicles in cancer, Nanomaterials, 7, 189, 10.3390/nano7070189

Roggers, 2014, The practicality of mesoporous silica nanoparticles as drug delivery devices and progress toward this goal, AAPS PharmSciTech, 15, 1163, 10.1208/s12249-014-0142-7

Nandiyanto, 2009, Synthesis of spherical mesoporous silica nanoparticles with nanometer-size controllable pores and outer diameters, Microporous Mesoporous Mater, 120, 447, 10.1016/j.micromeso.2008.12.019

Slowing, 2008, Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers, Adv Drug Deliv Rev, 60, 1278, 10.1016/j.addr.2008.03.012

Asefa, 2012, Biocompatibility of mesoporous silica nanoparticles, Chem Res Toxicol, 25, 2265, 10.1021/tx300166u

Lin, 2009, Synthesis and characterization of biocompatible and size-tunable multifunctional porous silica nanoparticles, Chem Mater, 21, 3979, 10.1021/cm901259n

Popat, 2012, A pH-responsive drug delivery system based on chitosan coated mesoporous silica nanoparticles, J Mater Chem, 22, 11173, 10.1039/c2jm30501a

Tang, 2012, Mesoporous silica nanoparticles: synthesis, biocompatibility and drug delivery, Adv Mater, 24, 1504, 10.1002/adma.201104763

Yamamoto, 2014, Preparation of size-controlled monodisperse colloidal mesoporous silica nanoparticles and fabrication of colloidal crystals, Chem Mater, 26, 2927, 10.1021/cm500619p

He, 2010, The effect of PEGylation of mesoporous silica nanoparticles on nonspecific binding of serum proteins and cellular responses, Biomaterials, 31, 1085, 10.1016/j.biomaterials.2009.10.046

Paris, 2015, Polymer-grafted mesoporous silica nanoparticles as ultrasound-responsive drug carriers, ACS Nano, 9, 11023, 10.1021/acsnano.5b04378

Yanes, 2012, Development of mesoporous silica nanomaterials as a vehicle for anticancer drug delivery, Ther Deliv, 3, 389, 10.4155/tde.12.9

Nadrah, 2014, Stimulus-responsive mesoporous silica particles, J Mater Sci, 49, 481, 10.1007/s10853-013-7726-6

Song, 2016, Mesoporous silica nanoparticles for stimuli-responsive controlled drug delivery: advances, challenges, and outlook, Int J Nanomed, 12, 87, 10.2147/IJN.S117495

Hergt, 2007, Magnetism in medicine, J Appl Phys, 404, 550

Hsiao, 2017, Preparation and characterization of multifunctional mesoporous silica nanoparticles for dual magnetic resonance and fluorescence imaging in targeted cancer therapy, Microporous Mesoporous Mater, 250, 210, 10.1016/j.micromeso.2017.04.050

Conde, 2012, Noble metal nanoparticles applications in cancer, J Drug Deliv, 2012, 751075, 10.1155/2012/751075

Chithrani, 2006, Determining the size and shape dependence of gold nanoparticle uptake into mammalian cells, Nano Lett, 6, 662, 10.1021/nl052396o

Applications, 2017, Unique roles of gold nanoparticles in drug delivery, targeting and imaging applications, Molecules, 22, 1445, 10.3390/molecules22091445

Noguez, 2007, Surface plasmons on metal nanoparticles: the influence of shape and physical environment, J Phys Chem C, 111, 3806, 10.1021/jp066539m

El-Sayed, 2005, Surface plasmon resonance scattering and absorption of anti-EGFR antibody conjugated gold nanoparticles in cancer diagnostics: applications in oral cancer, Nano Lett, 5, 829, 10.1021/nl050074e

Kimling, 2006, Turkevich method for gold nanoparticle synthesis revisited, J Phys Chem B, 110, 15700, 10.1021/jp061667w

Mafune, 2002, Full physical preparation of size-selected gold nanoparticles in solution: laser ablation and Laser induced size control, J Phys Chem B, 106, 7575, 10.1021/jp020577y

Song, 2009, Biological synthesis of gold nanoparticles using Magnolia kobus and Diopyros kaki leaf extracts, Process Biochem, 44, 1133, 10.1016/j.procbio.2009.06.005

Khan, 2014, Gold nanoparticles: synthesis and applications in drug delivery, Trop J Pharm Res, 13, 1169, 10.4314/tjpr.v13i7.23

Clark, 2015, Increased brain uptake of targeted nanoparticles by adding an acid-cleavable linkage between transferrin and the nanoparticle core, Proc Natl Acad Sci U S A, 112, 12486, 10.1073/pnas.1517048112

Dreaden, 2012, Size matters: gold nanoparticles in targeted cancer drug delivery, Ther Deliv, 3, 457, 10.4155/tde.12.21

Qian, 2011, Highly efficient and controllable PEGylation of gold nanoparticles prepared by femtosecond laser ablation in water, J Phys Chem C, 115, 23293, 10.1021/jp2079567

Yang, 2005, Transferrin-mediated gold nanoparticle cellular uptake, Bioconjug Chem, 16, 494, 10.1021/bc049775d

Han, 2007, Functionalized gold nanoparticles for drug delivery, Nanomedicine, 2, 113, 10.2217/17435889.2.1.113

Dixit, 2006, Synthesis and grafting of thioctic acid-PEG-folate conjugates onto Au nanoparticles for selective targeting of folate receptor-positive tumor cells, Bioconjug Chem, 17, 603, 10.1021/bc050335b

Yao, 2016, Gold nanoparticle mediated phototherapy for cancer, J Nanomater, 2016, 1

Tian, 2016, Stimuli-responsive gold nanoparticles for cancer diagnosis and therapy, J Funct Biomater, 7, 19, 10.3390/jfb7030019

Mendes, 2017, Gold nanoparticle approach to the selective delivery of gene silencing in cancer—the case for combined delivery?, Genes (Basel), 8, 94, 10.3390/genes8030094

Tiwari, 2011, Functionalized gold nanoparticles and their biomedical applications, Nanomaterials, 1, 31, 10.3390/nano1010031

Wahajuddin, 2012, Superparamagnetic iron oxide nanoparticles: magnetic nanoplatforms as drug carriers, Int J Nanomed, 7, 3445, 10.2147/IJN.S30320

Kodama, 1999, Magnetic nanoparticles, J Magn Magn Mater, 200, 359, 10.1016/S0304-8853(99)00347-9

Cano, 2016, Synthesis and characterization of multifunctional superparamagnetic iron oxide nanoparticles (SPION)/C 60 nanocomposites assembled by fullerene–amine click chemistry, RSC Adv, 6, 70374, 10.1039/C6RA14047E

Kandasamy, 2015, Recent advances in superparamagnetic iron oxide nanoparticles (SPIONs) for in vitro and in vivo cancer nanotheranostics, Int J Pharm, 496, 191, 10.1016/j.ijpharm.2015.10.058

Cole, 2011, Cancer theranostics: the rise of targeted magnetic nanoparticles, Trends Biotechnol, 29, 323, 10.1016/j.tibtech.2011.03.001

Patra, 2015, Dual-responsive polymer coated superparamagnetic nanoparticle for targeted drug delivery and hyperthermia treatment, ACS Appl Mater Interfaces, 7, 9235, 10.1021/acsami.5b01786

Mok, 2013, Superparamagnetic iron oxide nanoparticle-based delivery systems for biotherapeutics, Expert Opin Drug Deliv, 10, 73, 10.1517/17425247.2013.747507

Laurent, 2014, Superparamagnetic iron oxide nanoparticles for delivery of therapeutic agents: opportunities and challenges, Expert Opin Drug Deliv, 11, 1449, 10.1517/17425247.2014.924501

Santhosh, 2013, Multifunctional superparamagnetic iron oxide nanoparticles: promising tools in cancer theranostics, Cancer Lett, 336, 8, 10.1016/j.canlet.2013.04.032

Jeffreys, 1985, Individual-specific “fingerprints” of human DNA, Nature, 316, 76, 10.1038/316076a0

Krätschmer, 1990, Solid C60: a new form of carbon, Nature, 347, 354, 10.1038/347354a0

Liu, 2011, Carbon materials for drug delivery & cancer therapy, Mater Today, 14, 316, 10.1016/S1369-7021(11)70161-4

Iijima, 1991, Helical microtubules of graphitic carbon, Nature, 354, 56, 10.1038/354056a0

Cantoro, 2006, Catalytic chemical vapor deposition of single-wall carbon nanotubes at low temperatures, Nano Lett, 6, 1107, 10.1021/nl060068y

Eatemadi, 2014, Carbon nanotubes: properties, synthesis, purification, and medical applications, Nanoscale Res Lett, 1

Bianco, 2005, Applications of carbon nanotubes in drug delivery, Curr Opin Chem Biol, 9, 674, 10.1016/j.cbpa.2005.10.005

Li, 2017, Functionalized single-walled carbon nanotubes: cellular uptake, biodistribution and applications in drug delivery, Int J Pharm, 524, 41, 10.1016/j.ijpharm.2017.03.017

Lay, 2011, Functionalized carbon nanotubes for anticancer drug delivery, Expert Rev Med Devices, 8, 561, 10.1586/erd.11.34

Schmaljohann, 2006, Thermo- and pH-responsive polymers in drug delivery, Adv Drug Deliv Rev, 58, 1655, 10.1016/j.addr.2006.09.020

Wang, 2015, Functionalized carbon nanotubes: revolution in brain delivery, Nanomedicine, 10, 2639, 10.2217/nnm.15.114

Kafa, 2015, The interaction of carbon nanotubes with an in vitro blood-brain barrier model and mouse brain in vivo, Biomaterials, 53, 437, 10.1016/j.biomaterials.2015.02.083

Son, 2016, Carbon nanotubes as cancer therapeutic carriers and mediators, Int J Nanomed, 11, 5163, 10.2147/IJN.S112660

Seifalian, 2011, A new era of cancer treatment: carbon nanotubes as drug delivery tools, Int J Nanomed, 6, 2963, 10.2147/IJN.S16923

Chen, 2017, The advances of carbon nanotubes in cancer diagnostics and therapeutics, J Nanomater, 2017, 1

Matea, 2017, Quantum dots in imaging, drug delivery and sensor applications, Int J Nanomed, 12, 5421, 10.2147/IJN.S138624

Zrazhevskiy, 2010, Designing multifunctional quantum dots for bioimaging, detection, and drug delivery, Chem Soc Rev, 39, 4326, 10.1039/b915139g

Ghasemi, 2009, Quantum dot: magic nanoparticle for imaging, detection and targeting, Acta Biomed, 80, 156

Qi, 2008, Emerging application of quantum dots for drug delivery and therapy, Expert Opin Drug Deliv, 5, 263, 10.1517/17425247.5.3.263

Nakata, 2000, Molecular beam epitaxial growth of InAs self-assembled quantum dots with light-emission at 1.3μm, J Cryst Growth, 208, 93, 10.1016/S0022-0248(99)00466-2

Bertino, 2007, Quantum dots by ultraviolet and X-ray lithography, Nanotechnology, 18, 315603, 10.1088/0957-4484/18/31/315603

Valizadeh, 2012, Quantum dots: synthesis, bioapplications, and toxicity, Nanoscale Res Lett, 7, 480, 10.1186/1556-276X-7-480

Gui, 2014, Ratiometric and time-resolved fluorimetry from quantum dots featuring drug carriers for real-time monitoring of drug release in situ, Anal Chem, 86, 5211, 10.1021/ac501293e

Zhang, 2008, Quantum dots for cancer diagnosis and therapy: biological and clinical perspectives, Nanomedicine (Lond), 3, 83, 10.2217/17435889.3.1.83

Iannazzo, 2017, Graphene quantum dots for cancer targeted drug delivery, Int J Pharm, 518, 185, 10.1016/j.ijpharm.2016.12.060

Zhao, 2016, The research and applications of quantum dots as nano-carriers for targeted drug delivery and cancer therapy, Nanoscale Res Lett, 11, 207, 10.1186/s11671-016-1394-9

Kamal, 2012, Nanotechnology-based approaches in anticancer research, Int J Nanomed, 7, 4391, 10.2147/IJN.S33838

Senapati, 2018, Controlled drug delivery vehicles for cancer treatment and their performance, Signal Transduct Target Ther, 3, 7, 10.1038/s41392-017-0004-3

Gao, 2004, In vivo cancer targeting and imaging with semiconductor quantum dots, Nat Biotechnol, 22, 969, 10.1038/nbt994

Danhier, 2010, To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery, J Control Release, 148, 135, 10.1016/j.jconrel.2010.08.027

Mohanty, 2011, Receptor mediated tumor targeting: an emerging approach for cancer therapy, Curr Drug Deliv, 8, 45, 10.2174/156720111793663606

Matsumura, 1986, A new concept for macromolecular therapeutics in cancer-chemotherapy – mechanism of tumoritropic acumulation of proteins and the antitumor agent Smancs, Cancer Res, 46, 6387

Nakamura, 2016, Nanodrug delivery: is the enhanced permeability and retention effect sufficient for curing cancer?, Bioconjug Chem, 27, 2225, 10.1021/acs.bioconjchem.6b00437

Jain, 1987, Transport of molecules across tumor vasculature, Cancer Metastasis Rev, 6, 559, 10.1007/BF00047468

Heldin, 2004, High interstitial fluid pressure—an obstacle in cancer therapy, Nat Rev Cancer, 4, 806, 10.1038/nrc1456

Blanco, 2015, Principles of nanoparticle design for overcoming biological barriers to drug delivery, Nat Biotechnol, 33, 941, 10.1038/nbt.3330

Villiers, 2010, Analysis of the toxicity of gold nano particles on the immune system: effect on dendritic cell functions, J Nanoparticle Res, 12, 55, 10.1007/s11051-009-9692-0

Mura, 2013, Stimuli-responsive nanocarriers for drug delivery, Nat Mater, 12, 991, 10.1038/nmat3776

Liu, 2017, Internal stimuli-responsive nanocarriers for drug delivery: design strategies and applications, Mater Sci Eng C, 71, 1267, 10.1016/j.msec.2016.11.030

Vander Heiden, 2009, Understanding the Warburg effect: the metabolic requirements of cell proliferation, Science, 324, 1029, 10.1126/science.1160809

Gerweck, 1996, Cellular pH gradient in tumor versus normal tissue: potential exploitation for the treatment of cancer, Cancer Res, 56, 1194

Vaupel, 1989, Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review, Cancer Res, 49, 6449

Engin, 1995, Extracellular pH distribution in human tumours, Int J Hyperthermia, 11, 211, 10.3109/02656739509022457

Nilsson, 2003, Analysis of cytosolic and lysosomal pH in apoptotic cells by flow cytometry, Methods Cell Sci, 25, 185, 10.1007/s11022-004-8228-3

Gamcsik, 2012, Glutathione levels in human tumors, Biomarkers, 17, 671, 10.3109/1354750X.2012.715672

Meng, 2009, Reduction-sensitive polymers and bioconjugates for biomedical applications, Biomaterials, 30, 2180, 10.1016/j.biomaterials.2009.01.026

Wen, 2014, Redox sensitive nanoparticles with disulfide bond linked sheddable shell for intracellular drug delivery, Med Chem (Los Angeles), 4, 748, 10.4172/2161-0444.1000225

Cheng, 2011, Glutathione-responsive nano-vehicles as a promising platform for targeted intracellular drug and gene delivery, J Control Release, 152, 2, 10.1016/j.jconrel.2011.01.030

Andresen, 2010, Enzyme-triggered nanomedicine: drug release strategies in cancer therapy, Mol Membr Biol, 27, 353, 10.3109/09687688.2010.515950

Andresen, 2005, Advanced strategies in liposomal cancer therapy: problems and prospects of active and tumor specific drug release, Prog Lipid Res, 44, 68, 10.1016/j.plipres.2004.12.001

Meers, 2001, Enzyme-activated targeting of liposomes, Adv Drug Deliv Rev, 53, 265, 10.1016/S0169-409X(01)00205-8

Yao, 2016, External-stimuli responsive systems for cancer theranostic, Asian J Pharm Sci, 11, 585, 10.1016/j.ajps.2016.06.001

Hua, 2011, The effectiveness of a magnetic nanoparticle-based delivery system for BCNU in the treatment of gliomas, Biomaterials, 32, 516, 10.1016/j.biomaterials.2010.09.065

Plassat, 2011, Anti-estrogen-loaded superparamagnetic liposomes for intracellular magnetic targeting and treatment of breast cancer tumors, Adv Funct Mater, 21, 83, 10.1002/adfm.201001450

Bringas, 2012, Triggered release in lipid bilayer-capped mesoporous silica nanoparticles containing SPION using an alternating magnetic field, Chem Commun, 48, 5647, 10.1039/c2cc31563g

Hu, 2008, Core/single-crystal-shell nanospheres for controlled drug release via a magnetically triggered rupturing mechanism, Adv Mater, 20, 2690, 10.1002/adma.200800193

Hu, 2012, Multifunctional nanocapsules for simultaneous encapsulation of hydrophilic and hydrophobic compounds and on-demand release, ACS Nano, 6, 2558, 10.1021/nn205023w

Shao, 2011, The application of thermosensitive nanocarriers in controlled drug delivery, J Nanomater, 2011, 1, 10.1155/2011/389640

Kost, 2012, Responsive polymeric delivery systems, Adv Drug Deliv Rev, 64, 327, 10.1016/j.addr.2012.09.014

Yokoyama, 1996, Targetable drug carriers: present status and a future perspective, Adv Drug Deliv Rev, 21, 77, 10.1016/S0169-409X(96)00439-5

Topp, 1997, Thermosensitive micelle-forming block copolymers of poly(ethylene glycol) and poly(N-isopropylacrylamide), Macromolecules, 30, 8518, 10.1021/ma9710803

Klouda, 2008, Thermoresponsive hydrogels in biomedical applications, Eur J Pharm Biopharm, 68, 34, 10.1016/j.ejpb.2007.02.025

Lu, 2008, Light-activated nanoimpeller-controlled drug release in cancer cells, Small, 4, 421, 10.1002/smll.200700903

Yuan, 2012, Detection of serum human epididymis secretory protein 4 in patients with ovarian cancer using a label-free biosensor based on localized surface plasmon resonance, Int J Nanomed, 7, 2921, 10.2147/IJN.S32641

Yan, 2012, Functional mesoporous silica nanoparticles for photothermal-controlled drug delivery in vivo, Angew Chemie Int Ed, 51, 8373, 10.1002/anie.201203993

Yang, 2016, Near-infrared-light responsive nanoscale drug delivery systems for cancer treatment, Coord Chem Rev, 320–321, 100, 10.1016/j.ccr.2016.04.004

Rapoport, 2009, Controlled and targeted tumor chemotherapy by ultrasound-activated nanoemulsions/microbubbles, J Control Release, 138, 268, 10.1016/j.jconrel.2009.05.026

Dromi, 2007, Pulsed-high intensity focused ultrasound and low temperature-sensitive liposomes for enhanced targeted drug delivery and antitumor effect, Clin Cancer Res, 13, 2722, 10.1158/1078-0432.CCR-06-2443

Schroeder, 2009, Ultrasound, liposomes, and drug delivery: principles for using ultrasound to control the release of drugs from liposomes, Chem Phys Lipids, 162, 1, 10.1016/j.chemphyslip.2009.08.003

Geers, 2012, Crucial factors and emerging concepts in ultrasound-triggered drug delivery, J Control Release, 164, 248, 10.1016/j.jconrel.2012.08.014

Ge, 2012, Drug release from electric-field-responsive nanoparticles, ACS Nano, 6, 227, 10.1021/nn203430m

George, 2006, Electrically controlled drug delivery from biotin-doped conductive polypyrrole, Adv Mater, 18, 577, 10.1002/adma.200501242

Im, 2010, The effect of carbon nanotubes on drug delivery in an electro-sensitive transdermal drug delivery system, Biomaterials, 31, 1414, 10.1016/j.biomaterials.2009.11.004

Murdan, 2003, Electro-responsive drug delivery from hydrogels, J Control Release, 92, 1, 10.1016/S0168-3659(03)00303-1

Abidian, 2006, Conducting-polymer nanotubes for controlled drug release, Adv Mater, 18, 405, 10.1002/adma.200501726

Panzner, 1979, Control of in vitro cytotoxicity of positively charged liposomes, J Cancer Res Clin Oncol, 95, 29, 10.1007/BF00411106

Parnham, 1993, Toxicity screening of liposomes, Chem Phys Lipids, 64, 263, 10.1016/0009-3084(93)90070-J

Knudsen, 2015, In vivo toxicity of cationic micelles and liposomes, Nanomed Nanotechnol Biol Med, 11, 467, 10.1016/j.nano.2014.08.004

Filion, 1997, Toxicity and immunomodulatory activity of liposomal vectors formulated with cationic lipids toward immune effector cells, BBA, 1329, 345, 10.1016/S0005-2736(97)00126-0

Szebeni, 2009, Liposome triggering of innate immune responses: a perspective on benefits and adverse reactions, J Liposome Res, 19, 85, 10.1080/08982100902792855

Haber, 2010, Route of administration-dependent anti-inflammatory effect of liposomal alendronate, J Control Release, 148, 226, 10.1016/j.jconrel.2010.08.030

Goldsmith, 2011, Grand challenges in modulating the immune response with RNAi nanomedicines, Nanomedicine, 6, 1771, 10.2217/nnm.11.162

Dokka, 2000, Oxygen radical-mediated pulmonary toxicity induced by some cationic liposomes, Pharm Res, 17, 521, 10.1023/A:1007504613351

Mozafari, 2007, Cytotoxicity evaluation of anionic nanoliposomes and nanolipoplexes prepared by the heating method without employing volatile solvents and detergents, Pharmazie, 62, 205

Landesman-Milo, 2012, Altering the immune response with lipid-based nanoparticles, J Control Release, 161, 600, 10.1016/j.jconrel.2011.12.034

Roursgaard, 2016, In vitro toxicity of cationic micelles and liposomes in cultured human hepatocyte (HepG2) and lung epithelial (A549) cell lines, Toxicol In Vitro, 36, 164, 10.1016/j.tiv.2016.08.002

Kawaguchi, 2009, Histological study on side effects and tumor targeting of a block copolymer micelle on rats, J Control Release, 136, 240, 10.1016/j.jconrel.2009.02.011

Liu, 2017, Evaluation of in vitro toxicity of polymeric micelles to human endothelial cells under different conditions, Chem Biol Interact, 263, 46, 10.1016/j.cbi.2016.12.014

Kumar, 2012, In vitro evaluation of theranostic polymeric micelles for imaging and drug delivery in cancer, Theranostics, 2, 714, 10.7150/thno.3927

Gupta, 2015, Polymeric micelles and nanoemulsions as drug carriers: therapeutic efficacy, toxicity, and drug resistance, J Control Release, 212, 70, 10.1016/j.jconrel.2015.06.019

Li, 2009, Self-assembled polymeric micellar nanoparticles as nanocarriers for poorly soluble anticancer drug ethaselen, Nanoscale Res Lett, 4, 1502, 10.1007/s11671-009-9427-2

Knudsen, 2013, Differential toxicological response to positively and negatively charged nanoparticles in the rat brain, Nanotoxicology, 8, 1, 10.3109/17435390.2013.829589

Chung, 2015, In vivo biodistribution and clearance of peptide amphiphile micelles, Nanomed Nanotechnol Biol Med, 11, 479, 10.1016/j.nano.2014.08.006

Malik, 2000, Dendrimers, J Control Release, 65, 133, 10.1016/S0168-3659(99)00246-1

Leroueil, 2008, Wide varieties of cationic nanoparticles induce defects in supported lipid bilayers, Nano Lett, 8, 420, 10.1021/nl0722929

Asthana, 2005, Poly(amidoamine) (PAMAM) dendritic nanostructures for controlled sitespecific delivery of acidic anti-inflammatory active ingredient, AAPS PharmSciTech, 6, E536, 10.1208/pt060367

Agrawal, 2007, Glycoconjugated peptide dendrimers-based nanoparticulate system for the delivery of chloroquine phosphate, Biomaterials, 28, 3349, 10.1016/j.biomaterials.2007.04.004

Ziemba, 2011, In vivo toxicity of poly(propyleneimine) dendrimers, J Biomed Mater Res Part A, 99A, 261, 10.1002/jbm.a.33196

Sadekar, 2012, Transepithelial transport and toxicity of PAMAM dendrimers: implications for oral drug delivery, Adv Drug Deliv Rev, 64, 571, 10.1016/j.addr.2011.09.010

Pereira, 2011, In vivo biodistribution of carboxymethylchitosan/poly(amidoamine) dendrimer nanoparticles in rats, J Bioact Compat Polym, 26, 619, 10.1177/0883911511425567

Albertazzi, 2013, In vivo distribution and toxicity of PAMAM dendrimers in the central nervous system depend on their surface chemistry, Mol Pharm, 10, 249, 10.1021/mp300391v

Naha, 2018, Toxicology of engineered nanoparticles: focus on poly(amidoamine) dendrimers, Int J Environ Res Public Health, 15, 338, 10.3390/ijerph15020338

Padilla De Jesús, 2002, Polyester dendritic systems for drug delivery applications: in vitro and in vivo evaluation, Bioconjug Chem, 13, 453, 10.1021/bc010103m

Di Pasqua, 2008, Cytotoxicity of mesoporous silica nanomaterials, J Inorg Biochem, 102, 1416, 10.1016/j.jinorgbio.2007.12.028

Napierska, 2009, Size-dependent cytotoxicity of monodisperse silica nanoparticles in human endothelial cells, Small, 5, 846, 10.1002/smll.200800461

Ye, 2010, In vitro toxicity of silica nanoparticles in myocardial cells, Environ Toxicol Pharmacol, 29, 131, 10.1016/j.etap.2009.12.002

Heidegger, 2016, Immune response to functionalized mesoporous silica nanoparticles for targeted drug delivery, Nanoscale, 8, 938, 10.1039/C5NR06122A

Bibi, 2012, Trigger release liposome systems: local and remote controlled delivery?, J Microencapsul, 29, 262, 10.3109/02652048.2011.646330

So, 2008, Effect of micro/nano silica particle feeding for mice, J Nanosci Nanotechnol, 8, 5367, 10.1166/jnn.2008.1347

He, 2011, Mesoporous silica nanoparticle based nano drug delivery systems: synthesis, controlled drug release and delivery, pharmacokinetics and biocompatibility, J Mater Chem, 21, 5845, 10.1039/c0jm03851b

Ivanov, 2012, In vivo toxicity of intravenously administered silica and silicon nanoparticles, Materials (Basel), 5, 1873, 10.3390/ma5101873

Pan, 2007, Size-dependent cytotoxicity of gold nanoparticles, Small, 3, 1941, 10.1002/smll.200700378

Connor, 2005, Gold nanoparticles are taken up by human cells but do not cause acute cytotoxicity, Small, 1, 325, 10.1002/smll.200400093

Shukla, 2005, Biocompatibility of gold nanoparticles and their endocytotic fate inside the cellular compartment: a microscopic overview, Langmuir, 21, 10644, 10.1021/la0513712

Goodman, 2004, Toxicity of gold nanoparticles functionalized with cationic and anionic side chains, Bioconjug Chem, 15, 897, 10.1021/bc049951i

Alkilany, 2010, Toxicity and cellular uptake of gold nanoparticles: what we have learned so far?, J Nanoparticle Res, 12, 2313, 10.1007/s11051-010-9911-8

Chen, 2009, Assessment of the in vivo toxicity of gold nanoparticles, Nanoscale Res Lett, 4, 858, 10.1007/s11671-009-9334-6

De Jong, 2008, Particle size-dependent organ distribution of gold nanoparticles after intravenous administration, Biomaterials, 29, 1912, 10.1016/j.biomaterials.2007.12.037

Zhang, 2009, Influence of anchoring ligands and particle size on the colloidal stability and in vivo biodistribution of polyethylene glycol-coated gold nanoparticles in tumor-xenografted mice, Biomaterials, 30, 1928, 10.1016/j.biomaterials.2008.12.038

Balasubramanian, 2010, Biodistribution of gold nanoparticles and gene expression changes in the liver and spleen after intravenous administration in rats, Biomaterials, 31, 2034, 10.1016/j.biomaterials.2009.11.079

Jia, 2017, The in vitro and in vivo toxicity of gold nanoparticles, Chin Chem Lett, 28, 691, 10.1016/j.cclet.2017.01.021

Fratoddi, 2015, How toxic are gold nanoparticles? The state-of-the-art, Nano Res, 8, 1771, 10.1007/s12274-014-0697-3

Singh, 2010, Potential toxicity of superparamagnetic iron oxide nanoparticles (SPION), Nano Rev, 1, 5358, 10.3402/nano.v1i0.5358

Edge, 2016, Pharmacokinetics and bio-distribution of novel super paramagnetic iron oxide nanoparticles (SPIONs) in the anaesthetized pig, Clin Exp Pharmacol Physiol, 43, 319, 10.1111/1440-1681.12533

Jarockyte, 2016, Accumulation and Toxicity of superparamagnetic iron oxide nanoparticles in cells and experimental animals, Int J Mol Sci, 17, 1193, 10.3390/ijms17081193

Patil, 2018, Comprehensive cytotoxicity studies of superparamagnetic iron oxide nanoparticles, Biochem Biophys Reports, 13, 63, 10.1016/j.bbrep.2017.12.002

Wei, 2016, Iron overload by superparamagnetic iron oxide nanoparticles is a high risk factor in cirrhosis by a systems toxicology assessment, Sci Rep, 6, 29110, 10.1038/srep29110

Shi Kam, 2004, Nanotube molecular transporters: internalization of carbon nanotube−protein conjugates into mammalian cells, J Am Chem Soc, 126, 6850, 10.1021/ja0486059

Sayes, 2006, Functionalization density dependence of single-walled carbon nanotubes cytotoxicity in vitro, Toxicol Lett, 161, 135, 10.1016/j.toxlet.2005.08.011

Gaillard, 2011, Carbon nanotube-coupled cell adhesion peptides are non-immunogenic: a promising step toward new biomedical devices, J Pept Sci, 17, 139, 10.1002/psc.1290

Jain, 2011, Toxicity of multiwalled carbon nanotubes with end defects critically depends on their functionalization density, Chem Res Toxicol, 24, 2028, 10.1021/tx2003728

Allegri, 2016, Toxicity determinants of multi-walled carbon nanotubes: the relationship between functionalization and agglomeration, Toxicol Rep, 3, 230, 10.1016/j.toxrep.2016.01.011

Hatami, 2017, Toxicity assessment of multi-walled carbon nanotubes on Cucurbita pepo L. under well-watered and water-stressed conditions, Ecotoxicol Environ Saf, 142, 274, 10.1016/j.ecoenv.2017.04.018

Fujita, 2015, Size effects of single-walled carbon nanotubes on in vivo and in vitro pulmonary toxicity, Inhal Toxicol, 27, 207, 10.3109/08958378.2015.1026620

Hardman, 2006, A toxicologic review of quantum dots: toxicity depends on physicochemical and environmental factors, Environ Health Perspect, 114, 165, 10.1289/ehp.8284

Pelley, 2009, State of academic knowledge on toxicity and biological fate of quantum dots, Toxicol Sci, 112, 276, 10.1093/toxsci/kfp188

Bottrill, 2011, Some aspects of quantum dot toxicity, Chem Commun, 47, 7039, 10.1039/c1cc10692a

Wang, 2016, Immunotoxicity assessment of CdSe/ZnS quantum dots in macrophages, lymphocytes and BALB/c mice, J Nanobiotechnol, 14, 10, 10.1186/s12951-016-0162-4

Wu, 2014, Toxicity of quantum dots on respiratory system, Inhal Toxicol, 26, 128, 10.3109/08958378.2013.871762

Salykina YF, Zherdeva VV, Dezhurov SV, Wakstein MS, Shirmanova MV, Zagaynova EV, et al. Biodistribution and clearance of quantum dots in small animals. In: Tuchin VV, Genina EA, editors. 2010. p. 799908.

Choi, 2007, Renal clearance of quantum dots, Nat Biotechnol, 25, 1165, 10.1038/nbt1340

Libralato, 2017, Toxicity effects of functionalized quantum dots, gold and polystyrene nanoparticles on target aquatic biological models: a review, Molecules, 22, 1439, 10.3390/molecules22091439

Manshian, 2016, Evaluation of quantum dot cytotoxicity: interpretation of nanoparticle concentrations versus intracellular nanoparticle numbers, Nanotoxicology, 10, 1318, 10.1080/17435390.2016.1210691

Zhao, 2017, A comparison between sphere and rod nanoparticles regarding their in vivo biological behavior and pharmacokinetics, Sci Rep, 7, 4131, 10.1038/s41598-017-03834-2

Bednarski, 2015, The influence of the route of administration of gold nanoparticles on their tissue distribution and basic biochemical parameters: in vivo studies, Pharmacol Rep, 67, 405, 10.1016/j.pharep.2014.10.019

Naqvi, 2010, Concentration-dependent toxicity of iron oxide nanoparticles mediated by increased oxidative stress, Int J Nanomed, 5, 983, 10.2147/IJN.S13244

Bahadar, 2016, Toxicity of nanoparticles and an overview of current experimental models, Iran Biomed J, 20, 1

Zhang, 2017, Shape dependent cytotoxicity of PLGA-PEG nanoparticles on human cells, Sci Rep, 7, 1

Wang, 2008, Challenge in understanding size and shape dependent toxicity of gold nanomaterials in human skin keratinocytes, Chem Phys Lett, 463, 145, 10.1016/j.cplett.2008.08.039

Kermanizadeh, 2017, Hepatic toxicity assessment of cationic liposome exposure in healthy and chronic alcohol fed mice, Heliyon, 3, e00458, 10.1016/j.heliyon.2017.e00458

Ferrari, 2005, Cancer nanotechnology: opportunities and challenges, Nat Rev Cancer, 5, 161, 10.1038/nrc1566

Sanhai, 2008, Seven challenges for nanomedicine, Nat Nanotechnol, 3, 242, 10.1038/nnano.2008.114

Shi, 2017, Cancer nanomedicine: progress, challenges and opportunities, Nat Rev Cancer, 17, 20, 10.1038/nrc.2016.108

Tsoi, 2016, Mechanism of hard-nanomaterial clearance by the liver, Nat Mater, 15, 1212, 10.1038/nmat4718

Oberdörster, 2010, Safety assessment for nanotechnology and nanomedicine: concepts of nanotoxicology, J Intern Med, 267, 89, 10.1111/j.1365-2796.2009.02187.x

Yang, 2017, Toxicity assessment of nanoparticles in various systems and organs, Nanotechnol Rev, 6, 279, 10.1515/ntrev-2016-0047

Huang, 2017, Nanomedicine-based combination anticancer therapy between nucleic acids and small-molecular drugs, Adv Drug Deliv Rev, 115, 82, 10.1016/j.addr.2017.06.004

Das, 2015, Gene therapies for cancer: strategies, challenges and successes, J Cell Physiol, 230, 259, 10.1002/jcp.24791

Naldini, 2015, Gene therapy returns to centre stage, Nature, 526, 351, 10.1038/nature15818

Bosetti, 2015, Cost–effectiveness of nanomedicine: the path to a future successful and dominant market?, Nanomedicine, 10, 1851, 10.2217/nnm.15.74

Hare, 2017, Challenges and strategies in anti-cancer nanomedicine development: an industry perspective, Adv Drug Deliv Rev, 108, 25, 10.1016/j.addr.2016.04.025

Ventola, 2017, Progress in nanomedicine: approved and investigational nanodrugs, P T, 42, 742

Bobo, 2016, Nanoparticle-based medicines: a review of FDA-approved materials and clinical trials to date, Pharm Res, 33, 2373, 10.1007/s11095-016-1958-5

Pillai, 2014, Nanomedicines for cancer therapy: an update of FDA approved and those under various stages of development, SOJ Pharm Pharm Sci, 1, 1